Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Therapeutic Effect of Crizotinib in Patients With ALK-rearrangement-negative But High Expression of ALK Phosphorylation

NCT05792644 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT05792644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05792644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Therapeutic Effect of Crizotinib in Patients With ALK-rearrangement-negative But High Expression of ALK Phosphorylation
Lead sponsor
Harbin Medical University
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2018
Completion date
March 1, 2023
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk phosphorylation